Seek Returns logo

ISRG vs. VRTX: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ISRG and VRTX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolISRGVRTX
Company NameIntuitive Surgical, Inc.Vertex Pharmaceuticals Incorporated
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryHealth Care Equipment & SuppliesBiotechnology
Market Capitalization160.63 billion USD107.98 billion USD
ExchangeNasdaqGSNasdaqGS
Listing DateJune 16, 2000July 24, 1991
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of ISRG and VRTX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ISRG vs. VRTX: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolISRGVRTX
5-Day Price Return1.15%3.01%
13-Week Price Return-15.16%-12.07%
26-Week Price Return-9.41%-12.99%
52-Week Price Return-4.91%-6.12%
Month-to-Date Return0.19%7.54%
Year-to-Date Return-14.15%4.58%
10-Day Avg. Volume2.30M1.84M
3-Month Avg. Volume2.09M1.64M
3-Month Volatility25.42%47.73%
Beta1.680.31

Profitability

Return on Equity (TTM)

ISRG

15.55%

Health Care Equipment & Supplies Industry

Max
29.93%
Q3
16.99%
Median
9.28%
Q1
5.10%
Min
-12.52%

ISRG’s Return on Equity of 15.55% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.

VRTX

22.14%

Biotechnology Industry

Max
97.92%
Q3
11.99%
Median
-19.30%
Q1
-51.29%
Min
-132.03%

In the upper quartile for the Biotechnology industry, VRTX’s Return on Equity of 22.14% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

ISRG vs. VRTX: A comparison of their Return on Equity (TTM) against their respective Health Care Equipment & Supplies and Biotechnology industry benchmarks.

Net Profit Margin (TTM)

ISRG

28.51%

Health Care Equipment & Supplies Industry

Max
24.41%
Q3
13.71%
Median
10.08%
Q1
5.96%
Min
-5.58%

ISRG’s Net Profit Margin of 28.51% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

VRTX

31.86%

Biotechnology Industry

Max
73.34%
Q3
18.98%
Median
-12.96%
Q1
-105.72%
Min
-259.82%

A Net Profit Margin of 31.86% places VRTX in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.

ISRG vs. VRTX: A comparison of their Net Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Biotechnology industry benchmarks.

Operating Profit Margin (TTM)

ISRG

28.80%

Health Care Equipment & Supplies Industry

Max
31.09%
Q3
18.11%
Median
15.07%
Q1
8.48%
Min
-0.28%

An Operating Profit Margin of 28.80% places ISRG in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

VRTX

34.36%

Biotechnology Industry

Max
78.85%
Q3
21.90%
Median
-13.30%
Q1
-109.94%
Min
-278.10%

An Operating Profit Margin of 34.36% places VRTX in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

ISRG vs. VRTX: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Biotechnology industry benchmarks.

Profitability at a Glance

SymbolISRGVRTX
Return on Equity (TTM)15.55%22.14%
Return on Assets (TTM)13.75%15.87%
Net Profit Margin (TTM)28.51%31.86%
Operating Profit Margin (TTM)28.80%34.36%
Gross Profit Margin (TTM)66.61%86.11%

Financial Strength

Current Ratio (MRQ)

ISRG

5.64

Health Care Equipment & Supplies Industry

Max
5.19
Q3
3.00
Median
2.13
Q1
1.44
Min
0.86

ISRG’s Current Ratio of 5.64 is exceptionally high, placing it well outside the typical range for the Health Care Equipment & Supplies industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

VRTX

2.52

Biotechnology Industry

Max
16.97
Q3
8.39
Median
4.11
Q1
2.64
Min
0.74

VRTX’s Current Ratio of 2.52 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

ISRG vs. VRTX: A comparison of their Current Ratio (MRQ) against their respective Health Care Equipment & Supplies and Biotechnology industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ISRG

0.00

Health Care Equipment & Supplies Industry

Max
1.61
Q3
0.76
Median
0.45
Q1
0.14
Min
0.00

Falling into the lower quartile for the Health Care Equipment & Supplies industry, ISRG’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

VRTX

0.01

Biotechnology Industry

Max
1.92
Q3
0.79
Median
0.12
Q1
0.00
Min
0.00

VRTX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ISRG vs. VRTX: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Equipment & Supplies and Biotechnology industry benchmarks.

Interest Coverage Ratio (TTM)

ISRG

--

Health Care Equipment & Supplies Industry

Max
56.35
Q3
25.56
Median
9.60
Q1
3.78
Min
-26.49

Interest Coverage Ratio data for ISRG is currently unavailable.

VRTX

72.37

Biotechnology Industry

Max
72.37
Q3
1.03
Median
-9.59
Q1
-65.05
Min
-163.11

VRTX’s Interest Coverage Ratio of 72.37 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

ISRG vs. VRTX: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Equipment & Supplies and Biotechnology industry benchmarks.

Financial Strength at a Glance

SymbolISRGVRTX
Current Ratio (MRQ)5.642.52
Quick Ratio (MRQ)4.892.00
Debt-to-Equity Ratio (MRQ)0.000.01
Interest Coverage Ratio (TTM)--72.37

Growth

Revenue Growth

ISRG vs. VRTX: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ISRG vs. VRTX: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ISRG

0.00%

Health Care Equipment & Supplies Industry

Max
4.15%
Q3
1.76%
Median
0.79%
Q1
0.00%
Min
0.00%

ISRG currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

VRTX

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VRTX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ISRG vs. VRTX: A comparison of their Dividend Yield (TTM) against their respective Health Care Equipment & Supplies and Biotechnology industry benchmarks.

Dividend Payout Ratio (TTM)

ISRG

0.00%

Health Care Equipment & Supplies Industry

Max
160.00%
Q3
66.60%
Median
27.49%
Q1
0.00%
Min
0.00%

ISRG has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

VRTX

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VRTX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ISRG vs. VRTX: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Equipment & Supplies and Biotechnology industry benchmarks.

Dividend at a Glance

SymbolISRGVRTX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

ISRG

60.42

Health Care Equipment & Supplies Industry

Max
67.29
Q3
47.01
Median
30.94
Q1
23.91
Min
10.79

A P/E Ratio of 60.42 places ISRG in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

VRTX

29.02

Biotechnology Industry

Max
40.44
Q3
39.37
Median
22.12
Q1
15.76
Min
3.48

VRTX’s P/E Ratio of 29.02 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

ISRG vs. VRTX: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Equipment & Supplies and Biotechnology industry benchmarks.

Price-to-Sales Ratio (TTM)

ISRG

17.23

Health Care Equipment & Supplies Industry

Max
9.49
Q3
5.41
Median
2.86
Q1
2.07
Min
0.74

With a P/S Ratio of 17.23, ISRG trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

VRTX

9.24

Biotechnology Industry

Max
92.67
Q3
41.36
Median
8.45
Q1
4.46
Min
0.97

VRTX’s P/S Ratio of 9.24 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ISRG vs. VRTX: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Equipment & Supplies and Biotechnology industry benchmarks.

Price-to-Book Ratio (MRQ)

ISRG

10.85

Health Care Equipment & Supplies Industry

Max
10.85
Q3
6.56
Median
3.53
Q1
2.36
Min
0.71

ISRG’s P/B Ratio of 10.85 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

VRTX

6.66

Biotechnology Industry

Max
22.72
Q3
10.68
Median
4.55
Q1
2.44
Min
0.59

VRTX’s P/B Ratio of 6.66 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

ISRG vs. VRTX: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Equipment & Supplies and Biotechnology industry benchmarks.

Valuation at a Glance

SymbolISRGVRTX
Price-to-Earnings Ratio (TTM)60.4229.02
Price-to-Sales Ratio (TTM)17.239.24
Price-to-Book Ratio (MRQ)10.856.66
Price-to-Free Cash Flow Ratio (TTM)79.0030.16